Acne and hirsutism in polycystic ovary syndrome: Clinical, endocrine-metabolic and ultrasonographic differences

Gynecological Endocrinology

Volumn 16, Issue 4, 2002, Pages 275-284

  Fatsetti, L ^a   Gambera, A ^a   Andrico, S ^a   Sartori, E ^a  

^a NONE   (Italy)

Author keywords

3 androstanediol glucuronide; 5 reductase; Acne; Hair follicle; Hirsutism; Polycystic ovary syndrome; Sebaceous gland

Indexed keywords

ANDROSTANEDIOL; GLUCURONIDE; HYDROXYPROGESTERONE; INSULIN; LUTEINIZING HORMONE; SEX HORMONE BINDING GLOBULIN; SOMATOMEDIN BINDING PROTEIN 1; SOMATOMEDIN C;

ACNE VULGARIS; ADULT; AMENORRHEA; ARTICLE; CONTROLLED STUDY; ECHOGRAPHY; FEMALE; HIRSUTISM; HORMONE BLOOD LEVEL; HORMONE DETERMINATION; HUMAN; INCIDENCE; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; OBESITY; OLIGOMENORRHEA; ORAL GLUCOSE TOLERANCE TEST; OVARY POLYCYSTIC DISEASE; PATHOGENESIS; PRIORITY JOURNAL; RISK FACTOR; SYMPTOM;

EID: 0036693951     PISSN: 09513590     EISSN: None     Source Type: Journal    
DOI: 10.1080/gye.16.4.275.284     Document Type: Article

References (60)

1. Insulin secretion in obese and non-obese women with polycystic ovary syndrome and its relationship with hyperandrogenism
2. Sensitivity of plasma insulin levels in obese and non-obese women with functional hyperandrogenism
3. Clinical and biochemical features of polycystic ovarian disease
4. Hirsutism in polycystic ovary syndrome: Current concepts
5. Responses of serum gonadotrophins to LH-releasing hormone and oestrogens in Japanese women with polycystic ovaries
6. Heterogeneity of the polycystic ovary syndrome: Clinical, endocrine and ultrasound features in 556 patients
7. Management of post-acne scarring
8. Prevalence of facial acne in adults
9. Hyperandrogenemia in patients presenting acne
10. Androgen receptor in hirsutism and acne
11. Variable androgen sensitivity in relationship to hirsutism and acne
12. Feed-forward control of prostatic growth: Dihydrotestosterone induces expression of its own biosynthetic enzyme, steroid 5α-reductase
13. A twin study of polycystic ovary syndrome
14. Increased 5α-reductase activity in idiopathic hirsutism
15. 5α-reductase activity in the genital skin of hirsute women
16. Dihydrotestosterone is a peripheral paracrine hormone
17. Androstanediol glucuronide plasma clearance and production rates in normal and hirsute women
18. Serum levels of 3α-androstanediol glucuronide in hirsute and non-hirsute women
19. Metabolism of dihydrotestosterone to 5α-androstane and 3α, 17β-diol glucuronide is greater in the peripheral compartment than in the splanchnic compartment
20. Serum androsterone conjugates differentiate between acne and hirsutism in hyperandrogenic women
21. Two different pathogenetic mechanisms may play a role in acne and hirsutism
22. Androgen excess in cystic acne
23. Hirsutism, alopecia and acne
24. The response of the sebaceous glands of the hypophysectomized castrated male rat to 5α-androstanedione and 5α-androstane-3β, 17β-diol
25. The response of the sebaceous glands of the hypophysectomized castrated male rat to 5α-dihydrotestosterone, androstenedione, dehydroepiandrosterone and androsterone
26. The sebaceous glands: Twenty-five years of progress
27. The androgen control of sebum production. Study of subjects with dihydrotestosterone deficiency and complete androgen insensitivity
28. Deletion of steroid 5α-reductase 2 genes in male pseudohermaphroditism
29. Steroid 5α-reductase deficiency
30. Identification and selective inhibition of an isozyme of steroid 5α-reductase in human scalp
31. Predominant expression of 5α-reductase type 1 in pubic skin from normal subjects and hirsute patients
32. Tissue distribution and ontogeny of steroid 5α-reductase isozyme expression
33. Clinical assessment of body hair growth in women
34. Pilosebaceous physiology, in relation to hirsutism and acne
35. Ultrasound monitoring of ovarian follicular development: A comparison of real time and static scanning techniques
36. Multifollicular ovaries: Clinical and endocrine features and response to pulsatile gonadotropin releasing hormone
37. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance
38. Insulin resistance and lipid metabolism in polycystic ovary syndrome
39. Dysregulation of cytochrome P450c17α as the cause of polycystic ovary syndrome
40. Hyperandrogenism in polycystic ovary syndrome: Evidence of dysregulation of 11β-hydroxysteroid dehydrogenase
41. Pathophysiology of ovarian steroid secretion in polycystic ovary syndrome
42. Lean women with polycystic ovary, syndrome respond to insulin reduction with decreases in ovarian P450c17 activity and serum androgens
43. Decreases in ovarian P450c17 activity and serum free testosterone after reduction in insulin secretion in women with polycystic ovary syndrome
44. Classification of polycystic ovary, syndrome into three types according to response to human corticotropin-releasing hormone
45. Differential androgens response to adrenocorticotropic hormone stimulation in polycystic ovarian syndrome: Relationship with insulin secretion
46. Different responses of insulin, C-peptide, and testoterone to an oral glucose tolerance test in two groups of women with polycystic ovarian syndrome
47. Insulin and C-peptide secretion in non obese patients with polycystic ovarian disease
48. Insulin, somatotropic and luteinizing hormone axes in lean and obese women with polycystic ovary syndrome: Common and distinct features
49. Inappropriate gonadotropin secretion in polycystic ovary syndrome: Influence of adiposity
50. Role of insulin-like growth factor-1 (IGF-I) and IGF binding protein-1 (IGFBP-1) in the pathogenesis of polycystic ovary syndrome
51. Effects of luteinizing hormone, insulin, insulin-like growth factor-binding protein in patients with polycystic ovary syndrome
52. Low levels of low molecular weight insulin-like growth factor-binding protein in patients with polycystic ovary syndrome
53. Insulin and insulin-like growth factor I stimulate the proliferation of human ovarian theca - Interstitial cells
54. Growth factors and cytokines in hair follicle development and cycling: Recent insights from animal models and the potentials for clinical therapy
55. Regulation of human dermal papilla cell production of insulin-like growth factor binding protein-3 by retinoic acid, glucocorticoids, and insulin-like growth factor-1
56. Measurements of 3α, 17β-androstanediol glucuronide in serum and urine and the correlation with skin 5α-reductase activity
57. Efficacy of the combination ethinyl oestradiol and cyproterone acetate on the endocrine, clinical and ultrasonographic profile in polycystic ovarian syndrome
58. Management of hirsutism
59. Comparison of finasteride versus flutamide in the treatment of hirsutism
60. Balding hair follicle dermal papilla cells contain higher levels of androgens receptors than those from non-balding scalp